The first paper to be accepted by the AACR’s latest journal, Blood Cancer Discovery, was published online last week. The paper, which is freely available on the journal website, describes the landscape of mutations present in pediatric acute lymphoblastic leukemia (ALL) and how this landscape changes during treatment, leading to relapse.
Read More
The new year began with the good news that death rates from cancer are continuing their steady decline.
A study released this week by the American Cancer Society showed that from …
Around 400 BC, the Greek physician Hippocrates is believed to have first described tumors as “cancer,” using the words “karkinos” or “karkinoma,” which stem from the Greek word for “crab”. Today, hundreds of different types of cancer have been described. As our understanding of this group of diseases continues to grow, cancer prevention, detection, and treatment advancements continue to evolve.
Read More
The U.S. Food and Drug Administration (FDA) approved a new molecularly targeted therapeutic called fam-trastuzumab deruxtecan-nxki (Enhertu) for treating certain patients with breast cancer on Dec. 20, 2019. Specifically, it was approved for treating adults who have unresectable or metastatic HER2-positive breast cancer that has progressed despite treatment with two or more other HER2-targeted treatment regimens after the diagnosis of metastatic disease.
Read More
In the final days of 2019, the U.S. Food and Drug Administration (FDA) approved expanding the use of a previously approved molecularly targeted therapeutic called olaparib (Lynparza) to include treating certain patients diagnosed with one of the deadliest types of cancer—pancreatic cancer.
Read More
As the year winds down, here’s our final edition of Editors’ Picks for 2019. This regular feature highlights one “must read” article from each journal issue published by the AACR in a given month. This December, articles include results from three clinical trials, an evaluation of a first-in-class FGFR4 inhibitor, and an analysis of breast cancer survival disparities in New Jersey, among others. As always, articles highlighted here are freely available for a limited time.
Read More
This infographic explores immunotherapy, cancer treatment that uses the body’s immune system to attack cancer. This timeline illustrates a decade of progress in immunotherapy.
Read More
In the past few weeks, the U.S. Food and Drug Administration (FDA) has announced three approvals for new treatments for several types of cancer. On December 18, the FDA approved the new molecularly targeted therapeutic enfortumab vedotin-ejfv (Padcev) to treat certain patients who have bladder cancer; on November 21, the agency expanded the use of the molecularly targeted therapeutic acalabrutinib (Calquence) to include treating adults who have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL); and on November 14, it approved the new molecularly targeted therapeutic zanubrutinib (Brukinsa) to treat certain patients who have mantle cell lymphoma.
Read More
In 2019, research continued to drive progress across the spectrum of cancer care in the form of new and better ways to prevent, detect, diagnose, and treat some of the many diseases we call cancer. Here’s a look at some key developments in drug approvals, immunotherapy, precision medicine, and disparities research.
Read More
The National Cancer Institute’s Genomic Data Commons (GDC) has released data for 44,756 cancer cases from the American Association for Cancer Research’s Project Genomics Evidence Neoplasia Information Exchange, more simply known as AACR Project GENIE. This massive project was launched in 2015 with the goal of building an international, pan-cancer registry with tens of thousands of patients to empower precision oncology.
Read More
Immunotherapeutic advances have dramatically changed the treatment landscape for a host of different cancer types. Notably, immune checkpoint inhibitors – drugs that target the CTLA-4 or the PD-1/PD-L1 axis – have been approved for the treatment of more than a dozen cancers, and numerous clinical trials evaluating such agents in combination with other drugs are currently underway.
Read More